drugset
drugset / Trial / NCT03827668

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

NCT03827668 ↗

Phase 1 Completed 15 enrolled Pfizer
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the potential pharmacokinetic (PK) drug-drug interaction (DDI) between PF-06650833 and PF-06651600 in healthy adult participants.

Timeline

Start
2019-02-07
Primary completion
2019-04-29
Completion
2019-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritlecitinib Small molecule — —
Subject ZIMLOVISERTIB Small molecule — —

Indications

No indication recorded.